Literature DB >> 16809280

Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.

Eric A Weaver1, Zhongjing Lu, Zenaido T Camacho, Fatiha Moukdar, Hua-Xin Liao, Ben-Jiang Ma, Mark Muldoon, James Theiler, Gary J Nabel, Norman L Letvin, Bette T Korber, Beatrice H Hahn, Barton F Haynes, Feng Gao.   

Abstract

The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains is a serious challenge for HIV-1 vaccine design. We have generated a synthetic group M consensus env gene (CON6) for induction of cross-subtype immune responses and report here a comparative study of T-cell responses to this and natural strain env immunogens in a murine model. Three different strains of mice were immunized with CON6 as well as subtype A, B, or C env immunogens, using a DNA prime-recombinant vaccinia virus boost strategy. T-cell epitopes were mapped by gamma interferon enzyme-linked immunospot analysis using five overlapping Env peptide sets from heterologous subtype A, B, and C viruses. The CON6-derived vaccine was immunogenic and induced a greater number of T-cell epitope responses than any single wild-type subtype A, B, and C env immunogen and similar T-cell responses to a polyvalent vaccine. The responses were comparable to within-clade responses but significantly more than between-clade responses. The magnitude of the T-cell responses induced by CON6 (measured by individual epitope peptides) was also greater than the magnitude of responses induced by individual wild-type env immunogens. Though the limited major histocompatibility complex repertoire in inbred mice does not necessarily predict responses in nonhuman primates and humans, these results suggest that synthetic centralized env immunogens represent a promising approach for HIV-1 vaccine design that merits further characterization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809280      PMCID: PMC1489064          DOI: 10.1128/JVI.02484-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Consensus and ancestral state HIV vaccines.

Authors:  David C Nickle; Mark A Jensen; Geoffrey S Gottlieb; Daniel Shriner; Gerald H Learn; Allen G Rodrigo; James I Mullins
Journal:  Science       Date:  2003-03-07       Impact factor: 47.728

2.  Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.

Authors:  Bimal K Chakrabarti; Xu Ling; Zhi-Yong Yang; David C Montefiori; Amos Panet; Wing-Pui Kong; Brent Welcher; Mark K Louder; John R Mascola; Gary J Nabel
Journal:  Vaccine       Date:  2005-05-16       Impact factor: 3.641

3.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

4.  Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.

Authors:  Michael S Seaman; Ling Xu; Kristin Beaudry; Kristi L Martin; Margaret H Beddall; Ayako Miura; Anna Sambor; Bimal K Chakrabarti; Yue Huang; Robert Bailer; Richard A Koup; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.

Authors:  N A Doria-Rose; G H Learn; A G Rodrigo; D C Nickle; F Li; M Mahalanabis; M T Hensel; S McLaughlin; P F Edmonson; D Montefiori; S W Barnett; N L Haigwood; J I Mullins
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.

Authors:  M Shirai; C D Pendleton; J A Berzofsky
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

7.  Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein.

Authors:  X Zhan; K S Slobod; S Surman; S A Brown; T D Lockey; C Coleclough; P C Doherty; J L Hurwitz
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity.

Authors:  Scott A Brown; John Stambas; Xiaoyan Zhan; Karen S Slobod; Chris Coleclough; Amy Zirkel; Sherri Surman; Stephen W White; Peter C Doherty; Julia L Hurwitz
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

9.  Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.

Authors:  Wing-Pui Kong; Yue Huang; Zhi-Yong Yang; Bimal K Chakrabarti; Zoe Moodie; Gary J Nabel
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

Authors:  X Jin; D E Bauer; S E Tuttleton; S Lewin; A Gettie; J Blanchard; C E Irwin; J T Safrit; J Mittler; L Weinberger; L G Kostrikis; L Zhang; A S Perelson; D D Ho
Journal:  J Exp Med       Date:  1999-03-15       Impact factor: 14.307

View more
  45 in total

1.  Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells.

Authors:  Bangxing Hong; Xiao-Tong Song; Lisa Rollins; Lindsey Berry; Xue F Huang; Si-Yi Chen
Journal:  J Clin Invest       Date:  2011-01-04       Impact factor: 14.808

2.  Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis.

Authors:  Jae-Sung Yu; James W Peacock; Stacie Vanleeuwen; Tsungda Hsu; William R Jacobs; Mark J Cayabyab; Norman L Letvin; Richard Frothingham; Herman F Staats; Hua-Xin Liao; Barton F Haynes
Journal:  Clin Vaccine Immunol       Date:  2006-08-30

3.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

4.  Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells.

Authors:  Michael S Bennett; Hwee L Ng; Mirabelle Dagarag; Ayub Ali; Otto O Yang
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

5.  Immunogenicity of novel consensus-based DNA vaccines against avian influenza.

Authors:  Dominick J Laddy; Jian Yan; Natasha Corbitt; Gary P Kobinger; David B Weiner
Journal:  Vaccine       Date:  2007-01-30       Impact factor: 3.641

6.  Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences.

Authors:  Laura E Valentine; Shari M Piaskowski; Eva G Rakasz; Nathan L Henry; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

Review 7.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

Review 8.  T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Authors:  Bette T Korber; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

Review 9.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Magdalena E Sobieszczyk; Francine E McCutchan; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

Review 10.  HIV-1 vaccine development after STEP.

Authors:  Dan H Barouch; Bette Korber
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.